Trial Profile

Lenalidomide in Combination with Rituximab as Treatment for Patients with Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Rituximab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use

Most Recent Events

22 Jan 2018 Results (n=288) assessing clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia by taking data of this and other four studies, published in the Blood.
05 Jul 2014 Status changed from active, no longer recruiting to discontinued, as per M.D. Anderson Cancer Center record.
18 Apr 2013 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com